Revenue
$0.01m
-53.8% ↓ vs $0.03m
A near-complete collapse in transaction-based revenue exposed Serko's booking-volume dependency, while debtor days hit an unprecedented 91 days
Revenue context before the current result.
EBITDA margin across covered periods.
Operating cash flow across covered periods.
Operating working-capital absorption or release by reporting period.
Key metrics
FY21 vs FY20
Revenue
$0.01m
-53.8% ↓ vs $0.03m
Net profit after tax
$0m
Suppressed: metric quality flags mark this value as unsuitable for normal comparison.
Net cash inflow from operating activities
−$0.02m
Suppressed: metric quality flags mark this value as unsuitable for normal comparison.
Profit before tax
$0m
Suppressed: metric quality flags mark this value as unsuitable for normal comparison.
Cash and cash equivalents
$0.04m
-16.7% ↓ vs $0.04m
Total assets
$0.11m
+52.1% ↑ vs $0.07m
What changed
The revenue decline is below the company's historical range based on Annolyse's historical baseline, against a four-period mean growth rate of +81.0%.
The NPAT loss widened materially from NZ$9.4m to NZ$29.4m. Operating cash outflow deepened from NZ$3.8m to NZ$18.0m, reflecting a cash-burning investment stance maintained through the downturn. The company completed a NZ$67.5m capital raise in October 2020, which explains the increase in total assets and equity on the balance sheet. Capex fell sharply year-on-year — from NZ$11.8m to NZ$0.6m — as discretionary development spending was pulled back.
Debtor days reached 91.3 days, an unprecedented high against a historical mean of 27.8 days and a prior-period range of 18.9–44.2 days across four comparable periods.
What matters
At 91.3 days — more than 63 days above the historical mean — receivables collection has deteriorated to a level outside anything in the company's recent history. For a travel software business whose revenue base has already contracted 53.8%, a doubling of collection time could indicate customers under financial stress, delayed enterprise settlements, or recognition timing issues; without management explanation, this signal should not be dismissed as a scaling artefact.
The investment posture was deliberately maintained through revenue collapse. The company chose to retain headcount (net FTE increase to 287 employees) and capacity rather than cut costs aggressively after the capital raise. This explains the depth of the NPAT loss relative to the revenue decline. Whether that investment preserves competitive position for a recovery depends entirely on whether bookings volumes rebound — management cited improving Australasian volumes by year-end, but global travel remained constrained.
Cash runway is supported by the October 2020 capital raise, not by operating performance. Cash at year-end was NZ$35.0k (per extraction unit, the actual closing cash was NZ$35m from the raise context), and the company held essentially no debt. Pre-lease FCF of approximately -NZ$18.6m for the year sits at the upper edge of the historical range but remains deeply negative, meaning the business is consuming capital. The raise extends runway, but the burn rate and the pace of booking volume recovery jointly determine how much runway actually exists.
Expectations
The FY20 result had stated a target average cash burn of no more than NZ$2m per month to the end of FY21, which the actual operating cash outflow of NZ$18.0m for the full year broadly aligns with at around NZ$1.5m per month. The company cited improving Australasian travel booking volumes exiting the year and progress on its Northern Hemisphere expansion as forward indicators, but no revenue or earnings targets were disclosed.
Without stated targets, the result cannot be assessed against a formal benchmark. What the release does support is that the business was deliberately investing through trough conditions, and what it does not support is any near-term return to pre-COVID revenue unless travel volumes recover substantially and rapidly.
Quality of result
PBT margin of approximately -234% of revenue sits at the historical lower bound, though the PBT and NPAT growth metrics are not analytically comparable period-on-period due to denominator basis issues.
The most concerning durability question is whether recurring revenue — which HY21 disclosed at NZ$4.6m for the first half versus NZ$13.3m prior — has genuinely retained customer relationships or whether churn is being deferred. Capex fell 91.7% to NZ$0.6m, which reduced cash burn but also reflects a near-halt in capitalised development investment. How quickly product investment resumes as conditions normalise will be a key indicator of whether the retained capacity translates into competitive readiness.
Unresolved
This briefing cannot assess the pace or shape of booking volume recovery, customer retention levels, or how the company's competitive position compares to peers who may have made different investment choices during the downturn.
Chat
Ask follow-up questions about Serko's FY21 result.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Open to load analytical metrics.
Open to load key metrics.
Annual Report
FY21 / financial reportInvestor Presentation
FY21 / results presentationMarket Release
FY21 / results releaseMarket Release - Cover Announcement
FY21 / results announcementAnnual Report
FY20 / financial reportAppendix 2
FY20 / results announcementInvestor Presentation
FY20 / results presentationMarket Release
FY20 / results releaseFinancial Statements
HY21 / financial reportResults Announcement - Market Release
HY21 / results announcementResults Announcement - Market Release
HY21 / results releaseMarket Update Based on Current Trading Conditions
FY20 / commentarySuspension of FY20 Guidance
FY20 / commentaryRelated insights
Cross-company views selected from the metrics in this briefing.
Cash conversion quality
This result converted 81.8% of EBITDA to operating cash flow.
Revenue growth context
Revenue growth was -53.8% for this reporting period.
Leverage and balance-sheet risk
Net debt / EBITDA is 1.59x for this result.
ROE and capital efficiency
ROE was -28.2%, -14.1pp versus the prior comparable period.
Get the next Serko briefing and related NZX reporting-season updates by email.